Abstracts tagged "treatment and tofacitnib"

Abstract Number: 2332 • 2013 ACR/ARHP Annual Meeting
Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib
W. F. C. Rigby¹, L. Takiya², S. P. Wood³, H. Fan² and T. V. Jones², ¹Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Studies have shown an increased prevalence of diabetes mellitus…
Abstract Number: 2329 • 2013 ACR/ARHP Annual Meeting
Improvements In Physical Function Correlate With Improvements In Health Related Quality Of Life: Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib: Results From 3 Randomized Phase 3 Trials
V. Strand¹, R. E. Alten², C. I. Nduaka³, R. Riese³, D. Gruben³, S. H. Zwillich³, J. Andrews³ and G. Wallenstein³, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). RA affects all domains of health-related quality of…
Abstract Number: 2330 • 2013 ACR/ARHP Annual Meeting
Relationship Between Lymphocyte Count and Risk Of Infection In Rheumatoid Arthritis Patients Treated With Tofacitinib
R. F. van Vollenhoven¹, R. Riese², S. Krishnaswami², T. Kawabata², C. Fosser², S. Rottinghaus², M. Lamba² and S. H. Zwillich², ¹Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ²Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines involved in lymphocyte development, function and homeostasis…
Abstract Number: 1794 • 2013 ACR/ARHP Annual Meeting
The Jak Inihibitor Tofacitinib Suppresses Synovial Jak-Stat Signalling In Rheumatoid Arthritis
D. L Boyle¹, N. Wei², A. K. Singhal³, D. R. Mandel⁴, P Mease⁵, A. Kavanaugh⁶, R. Shurmur⁷, J. Hodge⁸, Z. Luo⁹, S. Krishnaswami¹⁰, D. Gruben⁹, S. H. Zwillich⁹, K. Soma⁹, J. D. Bradley⁹ and G. S. Firestein¹¹, ¹Div of Rheum, UCSD School of Medicine, La Jolla, CA, ²Arthritis Treatment Center, Frederick, MD, ³Southwest Rheumatology Research LLC, Mesquite, TX, ⁴Office of David R Mandel MD, Inc., Mayfield Village, OH, ⁵Seattle Rheumatology Associates, Seattle, WA, ⁶UCSD School of Medicine, La Jolla, CA, ⁷Associated Internal Medicine Specialists, Battle Creek, MI, ⁸Pfizer Inc, Collegeville, PA, ⁹Pfizer Inc, Groton, CT, ¹⁰Clinical Pharmacology, Pfizer Inc, Groton, CT, ¹¹Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The specific JAK-STAT (signal transducer and activator of…
Abstract Number: 440 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Safety Findings In Rheumatoid Arthritis Patients Treated With Tofacitinib, A Novel, Oral Janus Kinase Inhibitor
C. Charles-Schoeman¹, P Wicker², M. A. Gonzalez-Gay³, S. P. Wood⁴, M.G. Boy⁴, J. Geier⁵, D. Gruben⁴, K. Soma⁴ and R. Riese⁴, ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²PW Consulting LLC, Mystic, CT, ³Reumatologia, Hospital Marques De Valdecilla, Santander, Spain, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we evaluated the cardiovascular (CV) event rates and…
Abstract Number: 444 • 2013 ACR/ARHP Annual Meeting
Reversibility Of Pharmacodynamic Effects After Short- and Long-Term Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
M. C. Genovese¹, T. Kawabata², K. Soma², S. Menon², J.D. Clark³, J. Hodge⁴, L. Takiya⁴, R. Riese² and S. Krishnaswami⁵, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA, ⁵Clinical Pharmacology, Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). It has a short pharmacokinetic (PK) half-life of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].